98%
921
2 minutes
20
Objective: Preoperative left ventricular ejection fraction (LVEF) is one of the main predictors of outcomes in cardiac surgery. We present current era outcomes and associated direct cost in nonemergent isolated coronary artery bypass surgery (CABG) patients with LVEF <20% over the past 6 years and compare it with higher EF subgroups.
Methods: Six-year data from 2016 to 2022 at hospitals sharing Society of Thoracic Surgeons and financial data with Biome Analytics were analyzed based on 3 EF subgroups (EF ≤20%, EF 21% to 35%, and EF >35%). Outcomes and costs were assessed.
Results: Overall 30-day mortality of 12,649 patients was 1.9%. The EF ≤20% ( = 248), EF 21% to 35% ( = 1,408), and EF >35 ( = 10,993) cohorts had mortality of 6.9%, 3.7%, and 1.6%, respectively. The EF ≤20% subgroup had higher use of cardiopulmonary bypass, blood products, and mechanical support. In addition, the EF ≤20% subgroup had higher complication rates in almost all measured categories. Also, the EF ≤20% cohort had significantly higher length of stay, intensive care unit (ICU) hours, ICU and hospital readmissions, and lowest discharge to home rate. The strongest factors associated with mortality were postoperative cardiac arrest, renal failure requiring dialysis, extracorporeal membrane oxygenation, sepsis, prolonged ventilation, and gastrointestinal event. The overall median direct cost of care was $37,387.79 ($27,605.18, $51,720.96), with a median direct cost of care in the EF ≤20%, EF 21% to 35%, and EF >35% subgroups of $52,500.17 ($34,103.52, $80,806.79), $44,108.32 ($31,597.58, $63,788.03), and $36,521.80 ($27,168.91, $50,019.31), respectively.
Conclusions: In nonemergent isolated CABG surgery, low EF continues to have higher surgical risks and higher direct cost of care despite advances in cardiovascular care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/15569845231207335 | DOI Listing |
J Robot Surg
September 2025
Jinnah Postgraduate Medical Centre (JPMC), Karachi, Pakistan.
Arch Cardiovasc Dis
September 2025
Pharmacie, Nantes Université, CHU de Nantes, 44000 Nantes, France; UFR des Sciences Pharmaceutiques et Biologiques, Nantes Université, 44000 Nantes, France. Electronic address:
Background: Patients with acute coronary syndrome requiring coronary artery bypass graft surgery while on ticagrelor face a high risk of perioperative bleeding because of its strong antiplatelet effect. The Cytosorb® haemoadsorbent membrane (CytoSorbents Corporation, Princeton, NJ, USA), which is CE marked for ticagrelor removal, may help to mitigate this risk.
Aim: To evaluate the cost-revenue impact of the use of Cytosorb® membrane over two different time periods in a high-volume French hospital.
Bioorg Chem
September 2025
School of Cosmetic Science, Mae Fah Luang University, Chiang Rai 57100, Thailand. Electronic address:
Although antimicrobial peptides possess potent antimicrobial activities, the high cost of production, based on amino acid length, has limited their therapeutic and cosmeceutical applications. This study aimed to produce and characterize de novo designed antimicrobial peptides derived from WSKK11 and WSRR11 for efficacy against acne-causing bacteria. Ten designed peptides were evaluated for antimicrobial, hemolytic, and cytotoxic activities, as well as, secondary structures by FTIR and modes of action.
View Article and Find Full Text PDFEnviron Sci Technol
September 2025
The Grainger College of Engineering, Department of Civil and Environmental Engineering, University of Illinois Urbana-Champaign, Urbana, Illinois 61801, United States.
Wastewater solids management is a key contributor to the operational cost and greenhouse gas (GHG) emissions of water resource recovery facilities (WRRFs). This study proposes a 'waste-to-energy' strategy using a hydrothermal liquefaction (HTL)-based system to displace conventional energy- and emission-intensive practices. The proposed system directs HTL-produced biocrude to oil refineries and recovers regionally tailored nitrogen and phosphorus fertilizers.
View Article and Find Full Text PDFJ Med Econ
September 2025
Janssen Scientific Affairs, LLC, Titusville, New Jersey.
Objectives: To provide insights into the financial burden and opportunity cost of vision loss from retinitis pigmentosa (RP) in the US by using net present value (NPV) of direct medical and nonmedical costs.
Methods: Assumptions, including economic (discount rate, median income, cost-of-living, Social Security and Medicare taxes, public insurance/supplemental benefits, nutrition assistance, and prescription drug assistance), medical (federal National Health Expenditure tables, a recent retrospective claims analysis, and Optum Health claims database) and demographic (mortality rate, increase in mortality due to visual impairment, progression of blindness, probability of survival, retirement rate, rate of disability, and RP diagnosis probability) were made to develop a NPV model. Scenario analyses were performed on benefits and costs arising from patients with RP, if vision could be preserved via novel gene therapies.